SPOTLIGHT: CytRx stock plunges on trial halt


Shares of CytRx plunged on the news that the FDA had halted a mid-stage trial for a drug to treat Lou Gehrig's disease. Regulators want to take some time to analyze results from animal studies of arimoclomol. CytRx stock was down 38 percent on a rough day. Release | Report